Biomarker predicts KRASG12C inhibitor success in lung cancer treatment
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer ...
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...
Targeted Oncology1d
Exploring Zoldonrasib, Pan-RAS Inhibitors, and Future KRAS Therapies
Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...
stocknews1d
3 Biotech Stocks Revolutionizing Healthcare
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Targeted Oncology2d
Spira on ctDNA in KRAS G12D Pancreatic Cancer and Zoldonrasib
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
GEN3d
Insilico, U. Toronto Researchers Develop Quantum-Classical Computing AI Model
Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...
Amgen opens new drug substance facility in North Carolina, US
Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...